Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002034400 | SCV002310874 | uncertain significance | RASopathy | 2022-03-08 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with SOS1-related conditions. This variant is present in population databases (rs747801798, gnomAD 0.01%). This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 838 of the SOS1 protein (p.Cys838Tyr). |
Ambry Genetics | RCV002427515 | SCV002742529 | uncertain significance | Cardiovascular phenotype | 2023-05-17 | criteria provided, single submitter | clinical testing | The p.C838Y variant (also known as c.2513G>A), located in coding exon 16 of the SOS1 gene, results from a G to A substitution at nucleotide position 2513. The cysteine at codon 838 is replaced by tyrosine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV002468387 | SCV002763290 | uncertain significance | Noonan syndrome 4 | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV002468386 | SCV002763291 | uncertain significance | Fibromatosis, gingival, 1 | criteria provided, single submitter | clinical testing |